<!<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Company example • Pico.css</title>
  <meta name="description" content="A classic company or blog layout with a sidebar. Built with Pico CSS.">
  <link rel="shortcut icon" href="https://picocss.com/favicon.ico">
  <link rel="canonical" href="https://picocss.com/examples/company/">

  <!-- Pico.css -->
  <link rel="stylesheet" href="pico.min.css">

  <!-- Custom styles for this example -->
  <link rel="stylesheet" href="custom.css">
  <link rel="stylesheet" href="styles.css">
</head>
<body>
<section>
  <!-- Hero -->
  <div class="hero" data-theme="dark">
    <nav class="container-fluid">
      <ul class="main-navigation">
        <li><a href="./" class="contrast"><img src="GenomOncologyLogo_Mark.png" alt="Genome Oncology Logo"></a></li>
        <li>
      </ul>
      <div class="main_menu">
        <ul>
        </ul>
      </div>
    </nav>

  </div><!-- ./ Hero -->



  <form>
    <div class="container">
  <input type="search" id="search" name="search" placeholder="Search">
</div>
</form>
    <article id="article">
        <h3>First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation</h3>
        <p>The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JNJ-74699157 in participants with advanced solid tumors harboring a kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation (Part 1: Dose escalation) and to determine the safety and preliminaryantitumor activity of JNJ-74699157 at the  RP2D regimen in participants with advanced solid tumors harboring a KRAS G12C mutation (Part 2: Dose expansion).</p>
        <small>Primary Purpose:</small>
        <footer>
          <small>Recruitment Status:</small>
        </footer>
    </article>

</section>
<div class="container">
  <details>
    <summary>Trial Details</summary>
    <ul>
      <li>Trial Phase:</li>
      <li>Study Type:</li>
    </ul>
  </details>
  <details>
    <summary>Contact Details</summary>
    <ul></ul>
  </details>
  <!-- The div below contains the expanded details for this clinical trial-->
<div>
  <div class="container">
    <article>
      <details>
        <summary><strong>Detailed Description</strong></summary>
        <ul>
          <p>The study team will examine genetic changes, also known as mutations, in the DNA of participants' blood, or if applicable, bone marrow specimen. These types of tests are increasingly used by doctors to improve the accuracy of diagnosis and make decisions during care. This study seeks to understand how many patients will benefit from this testing, and in what ways. The results of this portion of the study are placed in the individual's medical record and are communicated back to each participant.
          </p>
        </ul>
      </details>
    </article>
    <article>
      <details>
        <summary><strong>Eligibility Requirements</strong></summary>
        <ul>
          <p>Inclusion Criteria: - Must have histopathologic confirmation of the particular rare hematologic disease. - Diseases that will be considered as rare hematologic diseases for this study will include the following - Langerhans cell histiocytosis (LCH) - Erdhiem Chester disease (ECD) - Rosai-Dorfman disease (RDD) - Miscellaneous histiocytic entities -indeterminate dendritic cell tumor, interdigitating dendritic cell sarcoma, follicular dendritic cell sarcoma, fibroblastic reticular cell tumor - Unicentric Castleman disease - Multicentric Castleman disease including TAFRO - Follicular Dendritic Cell sarcoma (FDCS) - Newly diagnosed treatment naïve patients as well as patients who received prior therapies (e.g. chemotherapy, targeted therapy, surgery, or radiation) will be included. -Tissue specimens collected within the past 5 yearse will be considered acceptable for study inclusion will include the following - Collected as part of the evaluation for diagnostic confirmation - Tissue specimen or extracted DNA (from blood sample) banked in IRB approved tissue repositories and obtained within five years prior to the date of informed consent. -Tissue samples are planned to be collectedfrom previously stored surgical specimens already being stored in pathology lab - Consent to have germline testing performed in parallel to tumor testingg)Patients willing to receive treatmen Exclusion Criteria: - Life expectancy of less than 6months - Patient unwilling to have germline testing performed on peripheral blood or buccal mucosa
          </p>
        </ul>
      </details>
    </article>
    <article>
      <details>
        <summary>
          <strong>Interventions</strong>
        </summary>
          <ul>
              <table>
                <thead>
                  <tr>
                    <th scope="col">Type</th>
                    <th scope="col">Name</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                      <td>Cell</td>
                      <td>Cell</td>
                  </tr>
                </tbody>
              </table>
          </ul>
        </summary>
      </details>
    </article>
  </div>
  <!-- div below will populate with each arm of the study-->
  <div class="container">
    <article>
      <details>
        <summary><strong>Arms</strong></summary>
        <ul>
          <article>
            <details>
              <summary>Arm 1</summary>
              <ul>
                <li>asdklfh lihoq aslhjoihd alasidhasi si siohodai os idoijoijs oijaja. aoihjhjos d oaihod oasiodih a.</li>
                <li></li>
              </ul>
            </details>
          </article>
          <article>
            <details>
              <summary>Arm 1</summary>
              <ul>
                <li>asdklfh lihoq aslhjoihd alasidhasi si siohodai os idoijoijs oijaja. aoihjhjos d oaihod oasiodih a.</li>
                <li></li>
              </ul>
            </details>
          </article>
          <article>
            <details>
              <summary>Arm 1</summary>
              <ul>
                <li>asdklfh lihoq aslhjoihd alasidhasi si siohodai os idoijoijs oijaja. aoihjhjos d oaihod oasiodih a.</li>
                <li></li>
              </ul>
            </details>
          </article>
        </ul>
      </details>
    </article>
  </div>
  <article id="article">
      <h4> Closest Location</h4>

  </article>
<footer>
  <div class="">
    <ul>

    </ul>
  </div>
</footer>
</body>
</html>
